Abnormalities of neural circuitry in Alzheimer's disease: Hippocampus and cortical cholinergic innervation

Neurology

Volumn 51, Issue 1 SUPPL., 1998, Pages

  Geula, Changiz ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; EARLY DIAGNOSIS; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PARASYMPATHETIC INNERVATION; PRIORITY JOURNAL;

EID: 0031904324     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.1_suppl_1.s18     Document Type: Article

References (108)

1. Sanides F. Functional architecture of motor and sensory cortices in primates in light of a new concept of neocortex evolution. In: Noback CR, Montagna W, eds. The primate brain. New York: Appleton-Century-Crofts, 1970:137-208.
2. Mesulam MM. Patterns of behavioral neuroanatomy: association areas, the limbic system and hemispheric specialization. In: Mesulam MM, ed. Principles of behavioral neurology. Philadelphia: FA Davis, 1985:1-70.
3. Van Hoesen GW, Pandya DN. Some connections of the entorhinal (area 28) and perirhinal (area 35) cortices of the rhesus monkey. I. Temporal lobe afferents. Brain Res 1975;95:1-24.
4. Pandya DN, Van Hoesen GW, Mesulam MM. Efferent connections of the cingulate gyrus in the rhesus monkey. Exp Brain Res 1981;42:319-330.
5. Mesulam MM, Mufson EJ. Insula of the old world monkey. Part III. Efferent cortical output and comments on function. J Comp Neurol 1982;212:38-52.
6. Rosene DL, Van Hoesen W. The hippocampal formation for the primate brain. A review of some comparative aspects of cytoarchitecture and connections. In: Jones EG, Peters A, eds. Cerebral cortex. 6th ed. New York: Plenum Publishing, 1987:345-456.
7. Geula C, Mesulam MM. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press, 1994:263-291.
8. Alzheimer A. A unique illness involving the cerebral cortex. In: Rothenberg DA, Hochberg FH, eds. Neurological classics in modern translation. London: Hafner Press, 1977:41-43.
9. Terry RD, Wisniewski HM. Ultrastructure of senile dementia and of experimental analogues. In: Gaitz CM, ed. Aging and the brain. New York: Plenum Press, 1972:89-116.
10. Lorenzo A, Yankner BA. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 1994;91:12243-12247.
11. Mena R, Wischik CM, Novak M, Milstein C, Cuello C. A progressive deposition of paired helical filaments (PHF) in the brain characterizes the evolution of dementia in Alzheimer's disease. J Neuropathol Exp Neurol 1991;50:474-490.
12. Trojanowski JQ, Shin RW, Schmidt ML, Lee VM. Relationship between plaques, tangles and dystrophic processes in Alzheimer's disease. Neurobiol Aging 1995;16:335-345.
13. Selkoe DJ. Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci 1994;17:489-517.
14. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996;16:921-932.
15. Rafalowski J, Barcikowska M, Wen GY, Wisniewski HM. Laminar distribution of neuritic plaques in normal aging, Alzheimer's disease and Down's syndrome. Acta Neuropathol (Berl) 1988;77:21-25.
16. Sparks DL, Hunsaker JC III, Scheff SW, Krysco RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 1990;11:601-607.
17. Giannakopoulos P, Hof PR, Mottier S, Michel JP, Bouras C. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol (Berl) 1994;87:456-468.
18. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42: 631-639.
19. Berg L, McCall DW, Miller JP, Morris JC. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol 1993; 50:349-358.
20. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cerebr Cortex 1991;1:103-116.
21. Geula C, Mesulam MM, Saroff DM, Wu CK. Relationship between plaques, tangles and loss of cortical cholinergic fibers in Alzheimer's disease. J Neuropathol Exp Neurol 1998; 57:63-75.
22. Coleman PD, Flood DG. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging 1987;8:521-545.
23. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41:17-24.
24. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-580.
25. Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 1990;11:29-37.
26. Catala I, Ferrer I, Galofre E, Fabregues I. Decreased numbers of dendritic spines on cortical pyramidal neurons in dementia. A quantitative Golgi study on biopsy samples. Hum Neurobiol 1988;6:255-259.
27. German DC, White CL III, Sparkman DR. Alzheimer's disease: neurofibrillary tangles in nuclei that project to the cerebral cortex. Neuroscience 1987;21:305-312.
28. Mann DMA, Yates PO, Marcyniuk B. Correlation between senile plaque and neurofibrillary tangle counts in cerebral cortex and neuronal counts in cortex and subcortical structures in Alzheimer's disease. Neurosci Lett 1985;56:51-55.
29. D'Amato RJ, Zweig RM, Whitehouse PJ, et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1987;22:229-236.
30. Insausti R, Tunon T, Sobreviela T, Insausti AM, Gonzalo LM. The human entorhinal cortex: a cytoarchitectonic analysis. J Comp Neurol 1995;355:171-198.
31. Insausti R, Amaral DG, Cowan WM. The entorhinal cortex of the monkey: II. Cortical afferents. J Comp Neurol 1987;264: 356-395.
32. Suzuki WA. Neuroanatomy of the monkey entorhinal, perirhinal and parahippocampal cortices: Organization of cortical inputs and interconnections with amygdala and striatum. Semin Neurosci 1996;8:3-12.
33. Stefanacci L, Suzuki WA, Amaral DG. Organization of connections between the amygdaloid complex and the perirhinal and parahippocampal cortices in macaque monkeys. J Comp Neurol 1996;375:552-582.
34. Suzuki WA, Amaral DG. Perirhinal and parahippocampal cortices of the macaque monkey: cortical afferents. J Comp Neurol 1994;350:497-533.
35. Witter MP, Amaral DG. Entorhinal cortex of the monkey: V. Projections to the dentate gyrus, hippocampus, and subicular complex. J Comp Neurol 1991;307:437-459.
36. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168-1170.
37. Van Hoesen GW, Hyman BT, Damasio AR. Cell-specific pathology in neural systems of the temporal lobe in Alzheimer's disease. Prog Brain Res 1986;70:321-335.
38. Braak H, Braak E. On areas of transition between entorhinal allocortex and temporal isocortex in the human brain. Normal morphology and lamina specific pathology in Alzheimer's disease. Acta Pathol 1985;68:325-332.
39. Braak H, Braak E. Neuropathological staging of Alzheimer's disease. Acta Neuropathol (Berl) 1991;82:239-259.
40. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991;12:295-312.
41. Lippa CF, Hamos JE, Pulaski-Salo D, DeGennaro LJ, Drachman DA. Alzheimer's disease and aging: effects on perforant pathways perikarya and synapses. Neurobiol Aging 1992;13: 405-411.
42. Davies DC, Horwood N, Isaacs SL, Mann DM. The effect of age and Alzheimer's disease on pyramidal neuron density in the individual fields of the hippocampal formation. Acta Neuropathol (Berl) 1992;83:510-517.
43. Flood DG. Region-specific stability of dendritic extent in normal human aging and regression in Alzheimer's disease. II. Subiculum. Brain Res 1991;540:83-95.
44. Hanks SD, Flood DG. Region-specific stability of dendritic extent in normal human aging and regression in Alzheimer's disease. I. CA1 of hippocampus. Brain Res 1991;540:63-82.
45. Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981;10:184-192.
46. Gomez-Isla T, Price JL, McKeel DWJ, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996;16:4491-4500.
47. Wakabayashi K, Honer WG, Masliah E. Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease. Brain Res 1994; 667:24-32.
48. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983;214: 170-197.
49. Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988;275:216-240.
50. Perry EK. The cholinergic system in old age and Alzheimer's disease. Age Aging 1980;9:1-8.
51. DeKosky ST, Harbaugh RE, Schmitt FA, et al. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlates. Ann Neurol 1992;32:625-632.
52. Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995;64:749-750.
53. Geula C, Mesulam MM. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cerebr Cortex 1996;6:165-177.
54. Lehericy S, Hirsch EC, Cervera-Pierot P, et al. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J Comp Neurol 1993;330:15-31.
55. Whitehouse PJ, Hedreen JC, White CL, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983;13:243-348.
56. Saper CB, German DC, White CL III. Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer's type: possible role in cell loss. Neurology 1985;35:1089-1095.
57. Mann DMA, Yates PO, Marcyniuk B. Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer's disease and their relationship to aging and to accumulation of lipofuscin pigment. Mech Aging Dev 1984;25:189-204.
58. Perry EK, Blessed G, Tomlinson BE, et al. Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes. Neurobiol Aging 1981;2:251-256.
59. Bowen DM, Benton JS, Spillane JA, Smith CCT, Allen SJ. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci 1982;57:191-202.
60. Mann DMA, Tucker CM, Yates PO. The topographic distribution of senile plaques and neurofibrillary tangles in the brains of non-demented persons of different ages. Neuropathol Appl Neurobiol 1987;13:123-139.
61. Mizutani T, Shimada H. Neuropathological background of twenty-seven centenarian brains. J Neurol Sci 1992;108: 168-177.
62. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992;42:1681-1688.
63. Geula C, Schatz CR, Mesulam MM. Differential localization of NADPH-diaphorase and calbindin-D28k within the cholinergic neurons of the basal forebrain, striatum and brainstem in the rat, monkey, baboon and human. Neuroscience 1993; 54:461-476.
64. Wu CK, Mesulam MM, Geula C. Age-related loss of calbindin from human basal forebrain cholinergic neurons. Neuroreport 1997;8:2209-2213.
65. Wu CK, Geula C. Selective loss of calbindin-D28k from cholinergic neurons of human basal forebrain in aging and Alzheimer's disease. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM, eds. Alzheimer's disease: biology, diagnosis and therapeutics. New York: John Wiley & Sons, 1997:297-302.
66. Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science 1991;253:1380-1386.
67. Squire LR, Zola-Morgan S. Memory: brain systems and behavior. Trends Neurol Sci 1988;11:170-175.
68. Grandes P, Streit P. Effect of perforant path lesion on pattern of glutamate-like immunoreactivity in rat dentate gyrus. Neuroscience 1991;41:391-400.
69. Baylis GC, Moore BO. Hippocampal lesions impair spatial response selection in the primate. Exp Brain Res 1994;98: 110-118.
70. Parkinson JK, Murray EA, Mishkin M. A selective mnemonic role for the hippocampus in monkeys: memory for the location of objects. J Neurosci 1988;8:4159-4167.
71. Parker A, Gaffan D. Mammillary body lesions in monkeys impair object-in-place memory: functional unity of the fornix-mammillary system. J Cogn Neurosci 1997;9:512-521.
72. Suzuki WA, Zola-Morgan S, Squire LR, Amaral DG. Lesions of the perirhinal and parahippocampal cortices in the monkey produce long-lasting memory impairment in the visual and tactual modalities. J Neurosci 1993;13:2430-2451.
73. Gaffan D. Dissociated effects of perirhinal cortex ablation, fornix transection and amygdalectomy: evidence for multiple memory systems in the primate temporal lobe. Exp Brain Res 1994;99:411-422.
74. Stoehr JD, Mobley SL, Roice D, et al. The effects of selective cholinergic basal forebrain lesions and aging upon expectancy in the rat. Neurobiol Learn Mem 1997;67:214-227.
75. Voytko ML, Olton DS, Richardson RT, Gorman LK, Tobin JR, Price DL. Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 1994;14: 167-186.
76. Walsh TJ, Herzog CD, Gandhi C, Stackman RW, Wiley RG. Injection of IgG 192-saporin into the medial septum produces cholinergic hypofunction and dose-dependent working memory deficits. Brain Res 1996;726:69-79.
77. Leanza G, Muir J, Nilsson OG, Wiley RG, Dunnett SB, Bjorklund A. Selective immunolesioning of the basal forebrain cholinergic system disrupts short-term memory in rats. Eur J Neurosci 1996;8:1535-1544.
78. Berger-Sweeney J, Heckers S, Mesulam MM, Wiley RG, Lappi DA, Sharma M. Differential effects on spatial navigation of immunotoxin-induced cholinergic lesions of the medial septal area and nucleus basalis magnocellularis. J Neurosci 1994;14:4507-4519.
79. Irle E, Markowitsch HL. Basal forebrain-lesioned monkeys are severely impaired in tasks of association and recognition memory. Ann Neurol 1987;22:735-743.
80. Winkler J, Suhr ST, Gage FH, Thai LJ, Fisher LJ. Essential role of neocortical acetylcholine in spatial memory. Nature 1995;375:484-487.
81. Dokla CP, Thal LJ. Effect of cholinesterase inhibitors on Morris water task behavior following lesions of the nucleus basalis magnocellularis. Behav Neurosci 1988;102:861-871.
82. Aigner TG, Mitchell SJ, Aggleton JP, et al. Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. Psychopharmacology 1987;92:292-300.
83. Drachman DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch Neurol 1974;30: 113-121.
84. Muir JL, Dunnett SB, Robbins TW, Everitt BJ. Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. Exp Brain Res 1992;89:611-622.
85. Wilcock GK, Esiri MM, Bowen DM, Smith CCT. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982;57:407-417.
86. Sandler R, Smith AD. Coexistence of GABA and glutamate in mossy fiber terminals of the primate hippocampus: an ultrastructural study. J Comp Neurol 1991;303:177-192.
87. Ottersen OP, Storm-Mathisen J. Different neuronal localization of aspartate-like and glutamate-like immunoreactivities in the hippocampus of rat, guinea pig and Senegalese baboon (Papio papio), with a note on the distribution of gamma-aminobutyrate. Neuroscience 1985;16:589-606.
88. Longson D, Longson CM, Jones EG. Localization of CAM II kinase-alpha, GAD, GluR2 and GABA(A) receptor subunit mRNAs in the human entorhinal cortex. Eur J Neurosci 1997;9:662-675.
89. Jansen KL, Faull RL, Dragunow M. Excitatory amino acid receptors in the human cerebral cortex: a quantitative autoradiographic study comparing the distributions of [3H]TCP, [3H]glycine, L-[3H]glutamate, [3H]AMPA and [3H]kainic , acid binding sites. Neuroscience 1989;32:587-607.
90. Ikonomovic MD, Sheffield R, Armstrong DM. AMPA-selective glutamate receptor subtype immunoreactivity in the aged human hippocampal formation. J Comp Neurol 1995;359:239-252.
91. Ikonomovic MD, Sheffield R, Armstrong DM. AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal formation of patients with Alzheimer's disease. Hippocampus 1995;5:469-486.
92. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 1996;40:759-766.
93. Ulas J, Brunner LC, Geddes JW, Choe W, Cotman CW. N-methyl-D-aspartate receptor complex in the hippocampus of elderly, normal individuals and those with Alzheimer's disease. Neuroscience 1992;49:45-61.
94. Hyman BT, Van Hoesen GW, Damasio AR. Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone. Ann Neurol 1987;22:37-40.
95. Sasaki H, Muramoto O, Kanazawa I, Arai H, Kosaka K, lizuka R. Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol 1986;19:263-269.
96. Geddes JW, Monaghan DT, Cotman CW, Lott IT, Kim RC, Chui HC. Plasticity of hippocampal circuitry in Alzheimer's disease. Science 1985;230:1179-1181.
97. Shaddock JG, Feuers RJ, Chou MW, Swenson DH, Casciano DA. Genotoxicity of tacrine in primary hepatocytes isolated from B6C3F1 mice and aged ad libitum and calorie restricted Fischer 344 rats. Mut Res 1995;344:79-88.
98. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-998.
99. Amberla K, Nordberg A, Viitanen M, Winblad B. Long-term treatment with tacrine (THA) in Alzheimer's disease - evaluation of neuropsychological data. Acta Neurol Scand 1993; 149:(suppl):55-57.
100. Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alz Dis Assoc Disord 1996;10:124-131.
101. Thal LJ, Schwartz G, Sano M, et al. A multicenter doubleblind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Neurology 1996;47:1389-1395.
102. Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. Arch Neurol 1997;54:836-840.
103. Geula C, Mesulam MM. Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Res 1989; 498:185-189.
104. Geula C, Mesulam MM. Cholinesterases and the pathology of Alzheimer's disease. Alz Dis Assoc Disord 1995;9:23-28.
105. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-473.
106. Raffaele KC, Asthana S, Berardi A, et al. Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimer's disease. Neuropsychopharmacology 1996;15:163-170.
107. Buccafusco JJ, Jackson WJ. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 1991;12:233-238.
108. Mouradian MM, Mohr E, Williams JA, Chase TN. No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Neurology 1988;38:606-608.